Myoview 30ml is a drug owned by Medi-physics Inc Dba Ge Healthcare. It is protected by 1 US drug patent filed in 2018 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 10, 2030. Details of Myoview 30ml's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9549999 | Radiopharmaceutical composition |
Mar, 2030
(4 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Myoview 30ml's patents.
Latest Legal Activities on Myoview 30ml's Patents
Given below is the list of recent legal activities going on the following patents of Myoview 30ml.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Jun, 2024 | US9549999 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Jun, 2020 | US9549999 |
| Patent Issue Date Used in PTA Calculation
Critical | 24 Jan, 2017 | US9549999 |
| Recordation of Patent Grant Mailed
Critical | 24 Jan, 2017 | US9549999 |
| Email Notification
Critical | 05 Jan, 2017 | US9549999 |
| Issue Notification Mailed
Critical | 04 Jan, 2017 | US9549999 |
| Dispatch to FDC | 19 Dec, 2016 | US9549999 |
| Application Is Considered Ready for Issue
Critical | 14 Dec, 2016 | US9549999 |
| Issue Fee Payment Received
Critical | 13 Dec, 2016 | US9549999 |
| Issue Fee Payment Verified
Critical | 13 Dec, 2016 | US9549999 |
US patents provide insights into the exclusivity only within the United States, but
Myoview 30ml is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Myoview 30ml's family patents as well as insights into
ongoing legal events
on those patents.
Myoview 30ml's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Myoview 30ml's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 10, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Myoview 30ml Generics:
There are no approved generic versions for Myoview 30ml as of now.
About Myoview 30ml
Myoview 30Ml is a drug owned by Medi-Physics Inc Dba Ge Healthcare. It is used for managing certain types of schizophrenia and bipolar disorder. Myoview 30Ml uses Technetium Tc-99M Tetrofosmin Kit as an active ingredient. Myoview 30Ml was launched by Medi-Physics in 1996.
Approval Date:
Myoview 30ml was approved by FDA for market use on 09 February, 1996.
Active Ingredient:
Myoview 30ml uses Technetium Tc-99m Tetrofosmin Kit as the active ingredient. Check out other Drugs and Companies using Technetium Tc-99m Tetrofosmin Kit ingredient
Treatment:
Myoview 30ml is used for managing certain types of schizophrenia and bipolar disorder.
Dosage:
Myoview 30ml is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| N/A | INJECTABLE | Prescription | INJECTION |